Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data.

Ther Adv Med Oncol · 2019 · PMC6552345 · PMID 31210799

Europe PMC DOI

hedged sentence

0.2100

closest p · 4.2× alpha

0.2100

boldest claim

The sentences

showed a trendp = 0.21not close (p > 0.1)

18 The experimental arm showed a trend towards longer mOS (19.4 versus 8.9 months for FOLFIRI and placebo, one sided p = 0.21).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.